ATAI Life Sciences N.V. (ATAI) Shares Decline Despite Market Challenges

ATAI Life Sciences N.V. (NASDAQ: ATAI)’s stock price has dropped by -0.63 in relation to previous closing price of 1.67. Nevertheless, the company has seen a loss of -10.78% in its stock price over the last five trading days. proactiveinvestors.com reported 2024-05-23 that atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously served as chief operating officer of Pacira Pharmaceuticals and as a portfolio manager of JP Morgan’s global healthcare fund, having started out as a practising physician.

Is It Worth Investing in ATAI Life Sciences N.V. (NASDAQ: ATAI) Right Now?

The 36-month beta value for ATAI is also noteworthy at 0.85. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for ATAI is 116.12M, and at present, short sellers hold a 5.43% of that float. The average trading volume of ATAI on May 23, 2024 was 1.56M shares.

ATAI’s Market Performance

ATAI’s stock has seen a -10.78% decrease for the week, with a -11.26% drop in the past month and a -9.32% fall in the past quarter. The volatility ratio for the week is 8.39%, and the volatility levels for the past 30 days are at 7.65% for ATAI Life Sciences N.V. The simple moving average for the last 20 days is -14.06% for ATAI’s stock, with a simple moving average of 2.07% for the last 200 days.

Analysts’ Opinion of ATAI

Many brokerage firms have already submitted their reports for ATAI stocks, with Maxim Group repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to Maxim Group is $6 based on the research report published on April 03, 2024 of the current year 2024.

Loop Capital, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $18. The rating they have provided for ATAI stocks is “Buy” according to the report published on November 01st, 2022.

Maxim Group gave a rating of “Buy” to ATAI, setting the target price at $25 in the report published on November 30th of the previous year.

ATAI Trading at -15.62% from the 50-Day Moving Average

After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.77% of loss for the given period.

Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 8.39%, as shares sank -8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.97% lower at present.

During the last 5 trading sessions, ATAI fell by -9.95%, which changed the moving average for the period of 200-days by -4.29% in comparison to the 20-day moving average, which settled at $1.9227. In addition, ATAI Life Sciences N.V. saw 17.70% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATAI starting from Brand Florian, who sale 151,303 shares at the price of $1.92 back on May 16 ’24. After this action, Brand Florian now owns 328,697 shares of ATAI Life Sciences N.V., valued at $290,502 using the latest closing price.

Rao Srinivas, the insider of ATAI Life Sciences N.V., sale 61,640 shares at $1.85 during a trade that took place back on Apr 02 ’24, which means that Rao Srinivas is holding 113,360 shares at $114,034 based on the most recent closing price.

Stock Fundamentals for ATAI

Current profitability levels for the company are sitting at:

  • -419.65 for the present operating margin
  • -0.64 for the gross margin

The net margin for ATAI Life Sciences N.V. stands at -122.03. The total capital return value is set at -0.46. Equity return is now at value -14.72, with -12.30 for asset returns.

Based on ATAI Life Sciences N.V. (ATAI), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.45. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -42.7.

Currently, EBITDA for the company is -125.15 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 985.52. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.83.

Conclusion

In summary, ATAI Life Sciences N.V. (ATAI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts